Abstract: The present disclosure describes the use of genetic variance information for folate transport or metabolism genes or pyrimidine transport or metabolism genes in the selection of effective methods of treatment of a disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.
Abstract: In one aspect, the present invention provides methods of determining susceptibility to bone fracture in a mammalian subject, wherein the methods comprise analyzing nucleic acid molecules obtained from the mammalian subject to determine which of the P, p X, and x alleles of the estrogen receptor ? gene are present, wherein the presence of a haplotype comprising the p and x alleles is indicative of an increased susceptibility to bone fracture. The present invention also provides kits for determining susceptibility to bone fracture in a mammalian subject.
Abstract: The present invention relates to methods for assessing an individual's susceptibility to treatment of an inflammatory disease with a dietary supplement. The invention describes the recognition that the sensitivity of an individual to the inflammation suppressing effects of fish oil on TNF-a production is linked both to genetic variation encoded by, or associated with, TNF-a and/or IL-6 single nucleotide polymorphisms and to the inherent level of production of TNF-a by cells.
Type:
Application
Filed:
December 10, 2009
Publication date:
July 22, 2010
Applicant:
Body Sync, Inc.
Inventors:
Robert Francis Grimble, Philip Charles Calder, William Martin Howell